Biogen Inc. CEDEAR (BIIBD)
BCBA
Closed
Aug 24, 2026
Day's Range
17.1952 wk Range
10.40Overview - BIIBD - Biogen Inc. CEDEAR
Key Statistics
Valuation
Enterprise Value
22.46B
P/E (Trailing)
‪0.08‬
Price / Book
‪0.81‬
EV / EBITDA
‪6.68‬
Profitability
Profit Margin
‪8.32%‬
Operating Margin
‪25.05%‬
Return on Assets
‪5.20%‬
Return on Equity
‪4.57%‬
Ownership
Float
881.55M
Held by Insiders
‪0.00%‬
Held by Institutions
‪0.00%‬
Price stats
Beta
‪0.16‬
50-Day Avg
‪16.04‬
200-Day Avg
‪14.16‬
Peers - BIIBD - Biogen Inc. CEDEAR
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on BCBA.
- BIIBDBCBABiogen Inc. CEDEAR+41.18%52-week change0.08P/E (Trailing)‪8.32%‬Profit Margin
- SANBCBABanco Santander, S.A. CEDEAR+43.62%52-week change60.24P/E (Trailing)‪33.46%‬Profit Margin
- JNJBCBAJohnson & Johnson CEDEAR+43.38%52-week change11.12P/E (Trailing)‪21.48%‬Profit Margin
- BMYBCBABristol-Myers Squibb Co.+40.06%52-week change5.24P/E (Trailing)‪18.87%‬Profit Margin
- MRKBCBAMerck & Co., Inc. CEDEAR+52.12%52-week change2.59P/E (Trailing)‪4.76%‬Profit Margin
- LLYBCBAEli Lilly and Company CEDEAR+52.71%52-week change0.20P/E (Trailing)‪33.52%‬Profit Margin
- AMGNBCBAAmgen Inc.+43.97%52-week change0.19P/E (Trailing)‪22.95%‬Profit Margin
Profile Summary - BIIBD - Biogen Inc. CEDEAR
About
Biogen Inc. is an American multinational biotechnology company specializing in treatments for neurological diseases and rare conditions. Based in Cambridge, Massachusetts, the company develops and commercializes a diverse portfolio of therapies including LEQEMBI and ADUHELM for Alzheimer's disease, TECFIDERA and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
